May 29th 2025
A patient and provider share updates on pelabresib plus Rituxan treatment, which met the MANIFEST-2 trial's primary end point for those with myelofibrosis.
May 27th 2025
March 10th 2025
March 7th 2025
March 6th 2025
May 26th 2025
May 21st 2025
May 17th 2025